Daily Newsletter

30 September 2024

Daily Newsletter

30 September 2024

LEO Pharma announces Enstilar NDA submission for plaque psoriasis in China

The NDA submission is backed by results from a study that enrolled 604 adults from China who have stable plaque psoriasis.

RanjithKumar Dharma September 30 2024

Leo Pharma has submitted a New Drug Application (NDA) to China's National Medical Products Administration for Enstilar, targeting the treatment of adult patients with plaque psoriasis.

Enstilar is an aerosol spray foam combining calcipotriol and betamethasone, designed to improve upon the existing Daivobet ointment, which is currently a standard treatment in China.

The submission follows a series of milestones for LEO Pharma in the EU and the US, with China potentially becoming the largest market for Enstilar.

The NDA is supported by a Phase III trial involving 604 adult Chinese subjects with stable plaque psoriasis.

This trial showed Enstilar to be superior to Daivobet ointment, achieving both primary and secondary endpoints.

The Center for Drug Evaluation (CDE) in China will now validate and fully evaluate the NDA. The regulatory review process is anticipated to be completed in the first half (H1) of 2026.

LEO Pharma China general manager Byron Yin said: “LEO Pharma strives to enhance patient care and elevate quality of life for those living with complex skin conditions like plaque psoriasis.

“Today’s submission is a crucial step towards offering a much-needed new treatment option in our region, in addition to the existing portfolio offering from LEO Pharma China.”

Enstilar is already indicated in the EU for up to four weeks of treatment for psoriasis vulgaris in adults, with suitable candidates eligible for long-term maintenance.

Recently, the European Commission authorised Leo Pharma's Anzupgo cream for treating adults with moderate to severe chronic hand eczema.

COPD Market Overview

Per our analysis, drug sales in the COPD drug market is expected to grow at a steady rate between 2023 and 2033, with an overall CAGR of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. Key topics covered in the report include an assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.

COPD Market Overview

Per our analysis, drug sales in the COPD drug market is expected to grow at a steady rate between 2023 and 2033, with an overall CAGR of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. Key topics covered in the report include an assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.

COPD Market Overview

Per our analysis, drug sales in the COPD drug market is expected to grow at a steady rate between 2023 and 2033, with an overall CAGR of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. Key topics covered in the report include an assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.

COPD Market Overview

Per our analysis, drug sales in the COPD drug market is expected to grow at a steady rate between 2023 and 2033, with an overall CAGR of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. Key topics covered in the report include an assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.

COPD Market Overview

Per our analysis, drug sales in the COPD drug market is expected to grow at a steady rate between 2023 and 2033, with an overall CAGR of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. Key topics covered in the report include an assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close